Brookline initiated coverage of Quince Therapeutics (QNCX) with a Buy rating and $9 price target Quince is advancing its AIDE technology platform that allows for encapsulation of a drug into a patient’s own red blood cells, the analyst tells investors in a research note. The firm sees a favorable risk-reward as EryDex advances through the clinic.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on QNCX:
- Quince Therapeutics management to meet with Maxim Group
- Quince Therapeutics presents data from prior Phase 3 ATTeST clinical trial
- Quince Therapeutics presents safety data from ATTeST trial at CNS meeting
- Quince Therapeutics initiated with a Buy at Maxim
- Quince Therapeutics initiated with a Buy at Rodman & Renshaw